Cargando…

Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease—a gut feeling

Acute graft-versus-host disease (aGvHD), post-allogeneic hematopoietic stem cell transplantation, is associated with high mortality rates in patients not responding to standard line care with steroids. Adoptive mesenchymal stromal cell (MSC) therapy has been established in some countries as a second...

Descripción completa

Detalles Bibliográficos
Autores principales: Gavin, Caroline, Boberg, Erik, Von Bahr, Lena, Bottai, Matteo, Andrén, Anton Törnqvist, Wernerson, Annika, Davies, Lindsay C., Sugars, Rachael V., Le Blanc, Katarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864966/
https://www.ncbi.nlm.nih.gov/pubmed/31747938
http://dx.doi.org/10.1186/s13287-019-1449-9
_version_ 1783471998143299584
author Gavin, Caroline
Boberg, Erik
Von Bahr, Lena
Bottai, Matteo
Andrén, Anton Törnqvist
Wernerson, Annika
Davies, Lindsay C.
Sugars, Rachael V.
Le Blanc, Katarina
author_facet Gavin, Caroline
Boberg, Erik
Von Bahr, Lena
Bottai, Matteo
Andrén, Anton Törnqvist
Wernerson, Annika
Davies, Lindsay C.
Sugars, Rachael V.
Le Blanc, Katarina
author_sort Gavin, Caroline
collection PubMed
description Acute graft-versus-host disease (aGvHD), post-allogeneic hematopoietic stem cell transplantation, is associated with high mortality rates in patients not responding to standard line care with steroids. Adoptive mesenchymal stromal cell (MSC) therapy has been established in some countries as a second-line treatment. Limitations in our understanding as to MSC mode of action and what segregates patient responders from non-responders to MSC therapy remain. The principal aim of this study was to evaluate the immune cell profile in gut biopsies of patients diagnosed with aGvHD and establish differences in baseline cellular composition between responders and non-responders to subsequent MSC therapy. Our findings indicate that a pro-inflammatory immune profile within the gut at the point of MSC treatment may impede their therapeutic potential. These findings support the need for further validation in a larger cohort of patients and the development of improved biomarkers in predicting responsiveness to MSC therapy.
format Online
Article
Text
id pubmed-6864966
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68649662019-12-12 Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease—a gut feeling Gavin, Caroline Boberg, Erik Von Bahr, Lena Bottai, Matteo Andrén, Anton Törnqvist Wernerson, Annika Davies, Lindsay C. Sugars, Rachael V. Le Blanc, Katarina Stem Cell Res Ther Letter Acute graft-versus-host disease (aGvHD), post-allogeneic hematopoietic stem cell transplantation, is associated with high mortality rates in patients not responding to standard line care with steroids. Adoptive mesenchymal stromal cell (MSC) therapy has been established in some countries as a second-line treatment. Limitations in our understanding as to MSC mode of action and what segregates patient responders from non-responders to MSC therapy remain. The principal aim of this study was to evaluate the immune cell profile in gut biopsies of patients diagnosed with aGvHD and establish differences in baseline cellular composition between responders and non-responders to subsequent MSC therapy. Our findings indicate that a pro-inflammatory immune profile within the gut at the point of MSC treatment may impede their therapeutic potential. These findings support the need for further validation in a larger cohort of patients and the development of improved biomarkers in predicting responsiveness to MSC therapy. BioMed Central 2019-11-20 /pmc/articles/PMC6864966/ /pubmed/31747938 http://dx.doi.org/10.1186/s13287-019-1449-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter
Gavin, Caroline
Boberg, Erik
Von Bahr, Lena
Bottai, Matteo
Andrén, Anton Törnqvist
Wernerson, Annika
Davies, Lindsay C.
Sugars, Rachael V.
Le Blanc, Katarina
Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease—a gut feeling
title Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease—a gut feeling
title_full Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease—a gut feeling
title_fullStr Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease—a gut feeling
title_full_unstemmed Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease—a gut feeling
title_short Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease—a gut feeling
title_sort tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease—a gut feeling
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864966/
https://www.ncbi.nlm.nih.gov/pubmed/31747938
http://dx.doi.org/10.1186/s13287-019-1449-9
work_keys_str_mv AT gavincaroline tissueimmuneprofilessupportingresponsetomesenchymalstromalcelltherapyinacutegraftversushostdiseaseagutfeeling
AT bobergerik tissueimmuneprofilessupportingresponsetomesenchymalstromalcelltherapyinacutegraftversushostdiseaseagutfeeling
AT vonbahrlena tissueimmuneprofilessupportingresponsetomesenchymalstromalcelltherapyinacutegraftversushostdiseaseagutfeeling
AT bottaimatteo tissueimmuneprofilessupportingresponsetomesenchymalstromalcelltherapyinacutegraftversushostdiseaseagutfeeling
AT andrenantontornqvist tissueimmuneprofilessupportingresponsetomesenchymalstromalcelltherapyinacutegraftversushostdiseaseagutfeeling
AT wernersonannika tissueimmuneprofilessupportingresponsetomesenchymalstromalcelltherapyinacutegraftversushostdiseaseagutfeeling
AT davieslindsayc tissueimmuneprofilessupportingresponsetomesenchymalstromalcelltherapyinacutegraftversushostdiseaseagutfeeling
AT sugarsrachaelv tissueimmuneprofilessupportingresponsetomesenchymalstromalcelltherapyinacutegraftversushostdiseaseagutfeeling
AT leblanckatarina tissueimmuneprofilessupportingresponsetomesenchymalstromalcelltherapyinacutegraftversushostdiseaseagutfeeling